A study to identify the prevalence of vulvovaginal candidiasis in second trimester
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20212644Keywords:
Preterm birth, Pregnancy, Vulvovaginal candidiasis, Candida albicans, Candidial infectionAbstract
Background: Vaginal candidial infections are due to excessive growth of Candida. These are normally present in the vagina in small numbers. Vaginal infections are typically caused by the yeast species Candida albicans. It is found that candidial infection increases the risk of preterm labour. Aims and objectives of the study were to determine the prevalence of vulvovaginal candidiasis and influence of maternal age, parity and weeks of 2nd trimester on its occurrence among pregnant women in 2nd trimester, attending the antenatal clinic in our hospital.
Methods: A prospective study conducted in BMCRI for a period of 3 months (October 2019-December 2019) on patients in second trimester. Consent of patients taken. High vaginal swabs were collected from the pregnant patients in second trimester and sent for culture. Candida positive cases were noted and results were analysed.
Results: A total of 100 high vaginal swabs were collected and reported in our study. Among them 54 swabs were positive for Candida growth (54%) and 46 swabs were negative for growth (46%). Culture positive patients’ clinical details were analysed and tabulated.
Conclusions: Our study concluded that candidiasis is more prevalent in pregnant women but there was no statistical significance in occurrence of vaginal candidiasis among various age groups, parity or trimester. Hence it is better to screen all the patients in I early II trimester in order to find out and treat positive cases early to prevent preterm births attributed to vaginal candidiasis.
References
Sobel J. Vaginal infections in adult women. Med Clin N Am. 1990;74(6):1573-602.
Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203-11.
Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-71.
Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009;144(1):68-71.
Fidel P. Host defense against oropharyngeal and vaginal candidiasis: site-specific differences. Rev Iberoam Micol. 1999;16:8-15.
Fidel P. Host defense against oropharyngeal and vaginal candidiasis: site-specific differences. Rev Iberoam Micol. 1999;16:8-15.
Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002;187(3):569-74.
Nelson M, Wanjiru W, Margaret MW. Prevalence of vaginal candidiasis and determination of the occurrence of Candida species in pregnant women attending the antenatal clinic of Thika District hospital. Kenya Open J Med Microbiol. 2013;3(4):264.
Fidel PL, Cutright J, Steele C. Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun. 2000;68(2):651-7.
Ellepola A, Samaranayake L. The effect of limited exposure to antimycotics on the relative cell-surface hydrophobicity and the adhesion of oral Candida albicans to buccal epithelial cells. Arch Oral Biol. 1998;43(11):879-87.
Ellepola A, Samaranayake L. The effect of limited exposure to antimycotics on the relative cell-surface hydrophobicity and the adhesion of oral Candida albicans to buccal epithelial cells. Arch Oral Biol. 1998;43(11):879-87.
Oviasogie F, Okungbowa F. Candida species amongst pregnant women in Benin city, Nigeria: effect of predisposing factors. Afr J Clin Exp Microbiol. 2009;10(2):92-8.
Abruquah H. Prevalence and antifungal susceptibility of Candida species isolated from women attending a gynaecological clinic in Kumasi, Ghana. J Sci Technology (Ghana). 2012;32(2):39-45.
Feglo P, Narkwa P. Prevalence and antifungal susceptibility patterns of yeast isolates at the Komfo Anokye teaching hospital (KATH), Kumasi, Ghana. 2012.
Sasikala G, Agatha D, Janagond BA, Thenmozhivalli PR. Characterization of Candida and its antifungal susceptibility pattern from patients with vaginal candidiasis in a Tertiiary care hospital in South India. J Pharmaceutical Biomed Sci. 2013;30(30):51-6.
Guideline vulvovaginal candidiasis of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infect immunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55(3):1-13.
Morrison EA, Cushman LF. Prevention of preterm delivery. N Engl J Med. 2007;357(19):1979.
Singh SI. Treatment of vulvovaginal candidiasis. Clin. Rev. CPJ/RPC. 2014;136(9):26-30.
Nurat AA, Babalola GO, Shittu MO. Detection and Epidemiology of Vulvovaginal Candidiasis among Asymptomatic Pregnant Women Attending a Tertiary Hospital in Ogbomoso, Nigeria. Int J Biomed Res. 2015;6(7).
Czeizel AE, Tóth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology. 1999;10(4):437-40.
Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69(5):751-5.
